Gapping up
In reaction to strong earnings/guidance: APP +6.1% (reports total net sales for March 2014 were flat year/year; comparable sales decreased 5% and wholesale net sales increased 11%; sees Q4 revs of 137.8 mln vs $136.12 mln single analyst estimate), CERE +5.3% (light volume), FAST +2.9%, WFC +1.6%.
Select metals/mining stocks trading higher: GOLD +0.7%, GDX +0.7%, AG +0.5%, GG +0.5%, GLD +0.4%, NEM +0.4%.
Other news: HRB +6.8% (reaches definitive agreement to divest its bank; expected to dilute H&R Block earnings by ~ $0.07 to $0.09 per share annually beginning in fiscal 2015), BOFI +6.1% (BofI Holding unit BofI Federal Bank agrees to provide banking products to H&R Block clients), ONCY +5.8% (ticking higher, collaborators present translational brain cancer clinical data and immunomodulatory preclinical research at UK Oncolytic Virus Conference; covered early clinical research showing that intravenously delivered REOLYSIN can cross the blood brain barrier to access tumours in the brains of humans), NEPT +4.6% (Haywood disclosed 9.9% stake in 13D; says ' Company should implement changes to the Board of Directors and management', ZNGA +2.2% (names David Lee as Chief Financial Officer and Chief Accounting Officer), INFY +1.4% (Board of Directors commences search for Mr. S.D. Shibulal's Successor), DIS +1.3% ( Maker Studios founders have failed a lawsuit to prevent DIS takeover, according to reports ), VISN +1.2% (announces strategic partnership with China Unicom), GTAT +1.2% (following positive MadMoney mention),WTT +0.8% (repurchased 4,815,110 shares of its common stock, representing ~ 20% of its total shares outstanding (prior to the repurchase), from its largest shareholder, Investcorp Technology Ventures and its affiliates, for an aggregate purchase price of ~ $9.6 mln, or $2.00 per share), GILD +0.8% ( Sovaldi demonstrates efficacy and safety among chronic Hepatitis C patients with advanced liver disease), WCG +0.7% (following late spike on blog suggesting M&A), DNDN +0.7% (immune responses enhanced and sustained when PROVENGE is given after androgen deprivation therapy in biochemically-recurrent prostate cancer), KIM +0.4% (acquires balance of KIF I Portfolio for $408 mln), ABBV +0.1% ( presents detailed Phase III results from SAPPHIRE-I and SAPPHIRE-II studies in chronic hepatitis C patients).
Analyst comments: PNW +2.5% (upgraded to Buy from Hold at Argus), SFLY +2.2% (upgraded to Buy from Neutral at Goldman; tgt raised to $52 from $47 ), IMPV +2.1% (upgraded to Buy from Neutral at Sterne Agee ), F +1% (upgraded to Buy from Hold at Deutsche Bank), AMTD +0.8% (upgraded to Overweight from Equal Weight at Barclays), CSX +0.5% (initiated with an Outperform at Macquarie), TM +0.4% (Toyota upgraded to Buy from Hold at Jefferies)
Select metals/mining stocks trading higher: GOLD +0.7%, GDX +0.7%, AG +0.5%, GG +0.5%, GLD +0.4%, NEM +0.4%.
Other news: HRB +6.8% (reaches definitive agreement to divest its bank; expected to dilute H&R Block earnings by ~ $0.07 to $0.09 per share annually beginning in fiscal 2015), BOFI +6.1% (BofI Holding unit BofI Federal Bank agrees to provide banking products to H&R Block clients), ONCY +5.8% (ticking higher, collaborators present translational brain cancer clinical data and immunomodulatory preclinical research at UK Oncolytic Virus Conference; covered early clinical research showing that intravenously delivered REOLYSIN can cross the blood brain barrier to access tumours in the brains of humans), NEPT +4.6% (Haywood disclosed 9.9% stake in 13D; says ' Company should implement changes to the Board of Directors and management', ZNGA +2.2% (names David Lee as Chief Financial Officer and Chief Accounting Officer), INFY +1.4% (Board of Directors commences search for Mr. S.D. Shibulal's Successor), DIS +1.3% ( Maker Studios founders have failed a lawsuit to prevent DIS takeover, according to reports ), VISN +1.2% (announces strategic partnership with China Unicom), GTAT +1.2% (following positive MadMoney mention),WTT +0.8% (repurchased 4,815,110 shares of its common stock, representing ~ 20% of its total shares outstanding (prior to the repurchase), from its largest shareholder, Investcorp Technology Ventures and its affiliates, for an aggregate purchase price of ~ $9.6 mln, or $2.00 per share), GILD +0.8% ( Sovaldi demonstrates efficacy and safety among chronic Hepatitis C patients with advanced liver disease), WCG +0.7% (following late spike on blog suggesting M&A), DNDN +0.7% (immune responses enhanced and sustained when PROVENGE is given after androgen deprivation therapy in biochemically-recurrent prostate cancer), KIM +0.4% (acquires balance of KIF I Portfolio for $408 mln), ABBV +0.1% ( presents detailed Phase III results from SAPPHIRE-I and SAPPHIRE-II studies in chronic hepatitis C patients).
Analyst comments: PNW +2.5% (upgraded to Buy from Hold at Argus), SFLY +2.2% (upgraded to Buy from Neutral at Goldman; tgt raised to $52 from $47 ), IMPV +2.1% (upgraded to Buy from Neutral at Sterne Agee ), F +1% (upgraded to Buy from Hold at Deutsche Bank), AMTD +0.8% (upgraded to Overweight from Equal Weight at Barclays), CSX +0.5% (initiated with an Outperform at Macquarie), TM +0.4% (Toyota upgraded to Buy from Hold at Jefferies)